Entecavir (Baraclude)

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Chronic Hepatitis B

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

Latest reported trial: NCT00035789 · Phase 3 · met primary endpoint · grade pending

Also approved (1)
EU
  • Baraclude is indicated for the treatment of chronic hepatitis B virus (HBV) infection in adults with: compensated liver disease and evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active inflammation and/or fibrosis; decompensated liver disease. For both compensated and decompensated liver disease, this indication is based on clinical trial data in nucleoside naive patients with HBeAg positive and HBeAg negative HBV infection. With respect to patients with lamivudine-refractory hepatitis B.
Product first approved 2006EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (24)
Chronic Hepatitis B
NCT06966232 · Sun Yat-sen University
2025-05-15 – 2027-05-20 · Gastrointestinal Cancers
What this study did
NCT03887702 · SWOG Cancer Research Network
2020-01-17 – 2022-12-20 · Hepatitis B Infection, Malignant Solid Neoplasm
What this study did
NCT02327416 · Tongji Hospital
2014-10 – 2019-06 · Hepatitis B, Chronic
What this study did
NCT01079806 · Bristol-Myers Squibb
2010-06-30 – 2018-03-31 · Chronic Hepatitis B Virus, Pediatric
What this study did
NCT01580202 · Seoul National University Hospital
2012-04 – 2017-06 · Malignancy, Hepatitis B
What this study did
NCT01369199 · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
2012-05 – 2017-02-14 · Hepatitis B
What this study did
NCT01368497 · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
2012-09 – 2016-12-23 · Hepatitis B
What this study did
NCT01694264 · Seoul National University Hospital
2012-09-01 – 2015-12-31 · Chronic Hepatitis B, Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Juvenile Idiopathic Arthritis
What this study did
NCT01046799 · HepNet Study House, German Liverfoundation
2008-03 – 2014-10 · Liver Transplantation, Hepatitis B, Liver Disease
What this study did
NCT01063036 · Bristol-Myers Squibb
2010-05 – 2014-02 · Chronic Hepatitis B
What this study did
NCT01220596 · Hanyang University
2010-06 – 2013-06 · Hepatitis B, Chronic
What this study did
NCT00065507 · Bristol-Myers Squibb
2003-08 – 2013-05 · Hepatitis B
What this study did
NCT00395018 · Bristol-Myers Squibb
2007-04 – 2011-03 · Hepatitis B, Chronic
What this study did
NCT00410072 · Bristol-Myers Squibb
2007-04 – 2010-10 · Hepatitis B, Chronic
What this study did
NCT00096785 · Bristol-Myers Squibb
2004-12 – 2008-04 · Hepatitis B, Chronic Disease
What this study did
NCT00975091 · Bristol-Myers Squibb
2004-05 – 2007-08 · Chronic Hepatitis B Virus
What this study did
NCT00036608 · Bristol-Myers Squibb
2002-01 – 2005-02 · Chronic Hepatitis B
What this study did
Other / comorbidity
NCT02650271 · Guangxi Medical University
2021-02-02 – 2023-12-30 · Hepatocellular Carcinoma
What this study did
Phase 2/3 (3)
Chronic Hepatitis B
NCT02555943 · Humanity and Health Research Centre
2015-02 – 2021-08 · Chronic Hepatitis C Infection, HBV Coinfection, Hepatitis B Reactivation
What this study did
NCT00051038 · Bristol-Myers Squibb
2002-09 – 2005-10 · Hepatitis B
What this study did
Other / comorbidity
NCT02829359 · Guangxi Medical University
2012-07 – 2015-12 · Liver Cancer
What this study did
Phase 2 (32)
Chronic Hepatitis B
NCT07267208 · Jongman Kim
2026-12-01 – 2027-12-31 · Hepatitis B Virus, Liver Transplant
What this study did
NCT05453435 · Sun Yat-sen University
2022-07-15 – 2027-05 · Resolved Hepatitis B, CD20 Positive B-cell Lymphoma
What this study did
NCT07145268 · Tanta University
2025-09-01 – 2026-09 · Liver Fibroses, HBV (Hepatitis B Virus)
What this study did
NCT04568265 · Ascentage Pharma Group Inc.
2020-06-03 – 2025-10-31 · Hepatitis B, Chronic Hep B, HBV
What this study did
NCT06990776 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
2025-07-09 – 2025-07-17 · Chronic Hepatitis B
What this study did
NCT04535544 · Janssen Research & Development, LLC
2020-09-17 – 2025-03-05 · Hepatitis D, Chronic
What this study did
NCT05382351 · Sun Yat-sen University
2022-05-10 – 2024-12-31 · Chronic Hepatitis B Virus Infection
What this study did
NCT05275023 · Janssen Research & Development, LLC
2022-06-30 – 2024-05-31 · Hepatitis B, Chronic
What this study did
NCT04585789 · Janssen Research & Development, LLC
2021-03-11 – 2024-01-09 · Hepatitis B
What this study did
NCT04667104 · Janssen Research & Development, LLC
2021-02-01 – 2023-04-17 · Hepatitis B, Chronic
What this study did
NCT04781647 · Assembly Biosciences
2021-02-18 – 2022-12-02 · Chronic Hepatitis B
What this study did
NCT05005507 · Janssen Research & Development, LLC
2021-11-03 – 2021-12-29 · Hepatitis B, Chronic
What this study did
NCT04189276 · Tasly Tianjin Biopharmaceutical Co., Ltd.
2019-12-10 – 2021-12 · Hepatitis B Virus (HBV)
What this study did
NCT02499562 · Shanghai Genomics, Inc.
2015-06-25 – 2020-11-20 · Hepatitis B, Chronic
What this study did
NCT02777814 · Sun Yat-sen University
2015-05-01 – 2019-11 · Colorectal Neoplasms
What this study did
NCT03577171 · Assembly Biosciences
2018-06-19 – 2019-06-21 · Chronic Hepatitis B
What this study did
NCT02777801 · Sun Yat-sen University
2015-06 – 2018-06 · Stomach Neoplasms
What this study did
NCT02577029 · Arrowhead Pharmaceuticals
2015-12 – 2016-12 · Hepatitis B, Hepatitis D
What this study did
NCT02738008 · Arrowhead Pharmaceuticals
2016-03 – 2016-12 · Hepatitis B
What this study did
NCT01914744 · Fudan University
2013-02 – 2016-12 · Non-Hodgkin Lymphoma, Hepatitis B Reactivation
What this study did
NCT02726789 · Replicor Inc.
2012-10 – 2016-12 · Hepatitis B, Chronic
What this study did
NCT01326546 · Chongqing Jiachen Biotechnology Ltd.
2010-06 – 2014-01 · Chronic Hepatitis B
What this study did
NCT01204762 · Bristol-Myers Squibb
2010-11 – 2013-12 · Hepatitis B Virus
What this study did
NCT01438424 · Bristol-Myers Squibb
2001-01 – 2011-04 · Hepatitis B Virus, HBV
What this study did
NCT01254994 · Sun Yat-sen University
2007-08 – 2010-12 · Liver Failure
What this study did
NCT01037062 · Bristol-Myers Squibb
2003-12 – 2006-12 · Chronic Hepatitis B
What this study did
NCT01022801 · Bristol-Myers Squibb
2003-08 – 2005-03 · Chronic Hepatitis B
What this study did
NCT01020565 · Bristol-Myers Squibb
2003-02 – 2005-02 · Chronic Hepatitis B
What this study did
NCT01037166 · Bristol-Myers Squibb
2002-12 – 2005-02 · Chronic Hepatitis B
What this study did
Phase 1/2 (5)
Chronic Hepatitis B
NCT06150014 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
2023-12-07 – 2026-09 · Chronic Hepatitis b
What this study did
NCT03109730 · Assembly Biosciences
2017-06-15 – 2018-06-12 · Chronic Hepatitis B
What this study did
NCT00423891 · Bristol-Myers Squibb
2007-06-30 – 2017-09-04 · Hepatitis B, Chronic
What this study did
NCT01589952 · Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
2012-03 – 2013-03 · Chronic Hepatitis B
What this study did
Phase 1 (18)
Chronic Hepatitis B
NCT07295873 · Beijing Continent Pharmaceutical Co, Ltd.
2026-03-15 – 2026-05-29 · Chronic Hepatitis B Liver Fibrosis, DDI (Drug-Drug Interaction)
What this study did
NCT04638439 · PharmaEssentia
2022-08-17 – 2026-04-08 · Chronic Hepatitis B Infection, Chronic Hepatitis D Infection
What this study did
NCT05550519 · Janssen Pharmaceutica N.V., Belgium
2022-10-31 – 2025-08-28 · Hepatitis B, Chronic
What this study did
NCT05123599 · Janssen Research & Development, LLC
2021-12-06 – 2024-06-26 · Hepatitis B, Chronic
What this study did
NCT05017116 · Suzhou Ribo Life Science Co. Ltd.
2021-08-09 – 2023-10-25 · Chronic Hepatitis B
What this study did
NCT05423106 · Janssen Research & Development, LLC
2022-07-04 – 2023-03-20 · Healthy, Hepatitis B, Chronic
What this study did
NCT03662568 · Sunshine Lake Pharma Co., Ltd.
2018-06-26 – 2019-06-10 · Chronic Hepatitis B
What this study did
NCT03469583 · Enyo Pharma
2018-02-12 – 2018-07-20 · Hepatitis B, Chronic
What this study did
NCT02908191 · Assembly Biosciences
2016-11 – 2018-06-12 · Chronic Hepatitis B
What this study did
NCT03083821 · Bristol-Myers Squibb
2017-05-16 – 2017-12-19 · Hepatitis B Virus
What this study did
NCT03032536 · Alios Biopharma Inc.
2017-01-31 – 2017-06-28 · Hepatitis B, Chronic Hepatitis B, Viral Hepatitis B
What this study did
NCT02797522 · Arrowhead Pharmaceuticals
2016-06 – 2016-11 · Hepatitis B
What this study did
NCT02288208 · TetraLogic Pharmaceuticals
2014-11 – 2015-05 · Hepatitis B
What this study did
NCT00994773 · Bader, Ted, M.D.
2009-12 – 2011-12 · Hepatitis B
What this study did
NCT01023230 · Dynavax Technologies Corporation
2009-09 – 2011-05 · Hepatitis B, Chronic
What this study did
Other / comorbidity
NCT04124081 · Beijing Continent Pharmaceutical Co, Ltd.
2019-05-15 – 2019-08-13 · Hydronidone
What this study did
NCT03239353 · Aucta Pharmaceuticals, Inc
2017-10-20 – 2018-06-20 · HBV
What this study did
Phase 4 (68)
Chronic Hepatitis B
NCT07345624 · Qing-Lei Zeng
2026-01-11 – 2030-12-31 · Hepatitis B Virus Infection, Children, Chronic Hepatitis B
What this study did
NCT07345611 · Qing-Lei Zeng
2026-01-11 – 2030-12-31 · Hepatitis B Virus Infection, Children, Chronic Hepatitis B
What this study did
NCT03933384 · Taichung Veterans General Hospital
2019-08-19 – 2030-12-31 · Hepatitis B, Viral Hepatitis
What this study did
NCT07189377 · University Health Network, Toronto
2025-09-24 – 2027-08 · Hepatitis B Virus (HBV), Lung Transplant Recipient
What this study did
NCT07816094 · Bangladesh Medical University
2026-01-01 – 2027-01-19 · Hepatitis B
What this study did
NCT02849132 · Beijing Friendship Hospital
2016-01 – 2025-12 · Hepatitis B, Liver Cirrhosis
What this study did
NCT03357822 · Tongji Hospital
2018-01-25 – 2022-07-25 · Chronic Hepatitis B
What this study did
NCT03308890 · Taipei Veterans General Hospital, Taiwan
2017-11-01 – 2022-04-30 · Chronic Hepatitis B
What this study did
NCT02945956 · ShuGuang Hospital
2018-04-05 – 2021-06 · Portal Hypertension
What this study did
NCT04069858 · Korea University
2016-12-01 – 2020-12-31 · Chronic Hepatitis B
What this study did
NCT03062813 · Guangdong Provincial People's Hospital
2017-02-01 – 2020-03-31 · Hepatitis B Virus Associated Nephrotic Syndrome
What this study did
NCT03332329 · Qin Ning
2015-12-01 – 2019-12-31 · Chronic Hepatitis b
What this study did
NCT01907230 · Taipei Veterans General Hospital, Taiwan
2013-09-10 – 2019-12-31 · Rheumatoid Arthritis, Hepatitis B Reactivation, Exposure to Hepatitis B Virus
What this study did
NCT02241590 · ShuGuang Hospital
2014-09 – 2019-06 · Liver Cirrhosis Due to Hepatitis B Virus
What this study did
NCT02241616 · ShuGuang Hospital
2014-09 – 2019-06 · Hepatitis B Virus Related Cirrhosis
What this study did
NCT03448744 · Wen-hong Zhang
2017-10-25 – 2018-12-30 · Chronic Hepatitis b
What this study did
NCT01925820 · National Taiwan University Hospital
2013-01 – 2018-12 · Chronic Hepatitis B
What this study did
NCT02973646 · Third Affiliated Hospital, Sun Yat-Sen University
2016-01 – 2018-12 · Chronic Hepatitis b
What this study did
NCT02281266 · Jia Fan
2015-01 – 2018-10 · Curable Hepatitis B Virus-Related Hepatocellular Carcinoma
What this study did
NCT02417207 · Third Affiliated Hospital, Sun Yat-Sen University
2015-04 – 2018-04 · Hepatitis B, Liver Transplantation
What this study did
NCT02097004 · Seoul National University Hospital
2014-04 – 2018-03-13 · Hepatitis B, Chronic
What this study did
NCT01768195 · Peking University
2013-01 – 2017-12 · Hepatitis B
What this study did
NCT01765231 · Peking University
2013-01 – 2017-12 · Hepatitis B
What this study did
NCT01639066 · Asan Medical Center
2012-09-25 – 2017-09-22 · Chronic Viral Hepatitis B Without Delta-agent
What this study did
NCT02482272 · Asan Medical Center
2015-05 – 2017-05 · Hepatitis B, Chronic
What this study did
NCT02560649 · Ruijin Hospital
2015-05 – 2017-02 · Chronic Hepatitis B
What this study did
NCT01834508 · Nanfang Hospital, Southern Medical University
2013-03 – 2016-12 · Chronic Hepatitis B
What this study did
NCT02365402 · Beijing Ditan Hospital
2013-01 – 2016-12 · Chronic Hepatitis B
What this study did
NCT02368288 · Beijing Ditan Hospital
2013-01 – 2016-12 · Chronic Hepatitis B
What this study did
NCT01711567 · Korea University
2013-04 – 2016-11 · Chronic Hepatitis B
What this study did
NCT01456312 · Gangnam Severance Hospital
2012-09 – 2016-08 · Hepatitis B, Chronic
What this study did
NCT01906580 · Beijing 302 Hospital
2011-07 – 2016-07 · Chronic Hepatitis B
What this study did
NCT01829685 · Nanfang Hospital, Southern Medical University
2013-03 – 2016-06 · Chronic Hepatitis B, Inadequate Response, Nucleos(t)Ide Analogues Treatment
What this study did
NCT01627223 · Taichung Veterans General Hospital
2012-07 – 2016-04 · Chronic Hepatitis B
What this study did
NCT01913431 · Dong-A ST Co., Ltd.
2013-09-12 – 2015-11-06 · HBeAg-Positive Chronic Hepatitis B
What this study did
NCT00823550 · Yonsei University
2009-01 – 2015-07 · Hepatitis B, Chronic
What this study did
NCT01833611 · National Cheng-Kung University Hospital
2008-09 – 2015-05 · Chronic Hepatitis
What this study did
NCT01341106 · RWTH Aachen University
2011-04 – 2015-04 · Hepatitis B, Chronic, Liver Fibrosis
What this study did
NCT01341743 · Nanfang Hospital, Southern Medical University
2010-12 – 2014-12 · Hepatitis B
What this study did
NCT01179594 · Hoffmann-La Roche
2010-09-18 – 2014-11 · Hepatitis B, Chronic
What this study did
NCT00922207 · Hoffmann-La Roche
2010-05-07 – 2014-09-29 · Hepatitis B, Chronic
What this study did
NCT01597934 · Yonsei University
2012-08 – 2014-05 · Chronic Hepatitis B
What this study did
NCT01594905 · Yonsei University
2012-08 – 2014-04 · Chronic Hepatitis B
What this study did
NCT01926288 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
2008-10 – 2014-03 · Chronic Hepatitis B
What this study did
NCT00597259 · National Taiwan University Hospital
2008-01 – 2014-02 · Chronic Hepatitis B
What this study did
NCT00921180 · National Taiwan University Hospital
2007-02 – 2013-12 · Hepatitis B, Chronic
What this study did
NCT00917761 · National Taiwan University Hospital
2007-02 – 2013-12 · Hepatitis B, Chronic
What this study did
NCT00393484 · Bristol-Myers Squibb
2007-02 – 2013-09 · Chronic Hepatitis B
What this study did
NCT00877760 · Foundation for Liver Research
2009-08 – 2013-07 · Chronic Hepatitis B
What this study did
NCT00663182 · Shanghai Changzheng Hospital
2008-01 – 2012-12 · Hepatitis B Virus, Decompensated Cirrhosis
What this study did
Early phase / not applicable (21)
Chronic Hepatitis B
NCT04942886 · Seoul St. Mary's Hospital
2021-08-21 – 2028-12-31 · Hepatitis B Reactivation, Hematopoietic Stem Cell Transplantation, Antiviral Drug, HBV
What this study did
NCT07253220 · Sun Yat-sen University
2025-12-01 – 2028-09-30 · Hepatitis B, Hepatocellular Carcinoma (HCC)
What this study did
NCT05792761 · Fang Wang
2021-05-06 – 2025-12-31 · Chronic HBV Infection
What this study did
NCT04195074 · Third Affiliated Hospital, Sun Yat-Sen University
2019-01-01 – 2024-12-31 · Chronic Hepatitis b
What this study did
NCT05721300 · Zhongshan Hospital (Xiamen), Fudan University
2023-02-10 – 2024-12-31 · Hepatocellular Carcinoma, Chronic Hepatitis B
What this study did
NCT04199819 · The University of Hong Kong
2022-01-01 – 2023-12-31 · Occult Hepatitis B, Liver Transplant; Complications
What this study did
NCT03733652 · Third Affiliated Hospital, Sun Yat-Sen University
2018-11-15 – 2021-12-31 · Chronic Hepatitis b, Efficacy, Self
What this study did
NCT03164889 · Beijing 302 Hospital
2017-01 – 2021-12-01 · Hepatitis B, Chronic
What this study did
NCT04182321 · Fu-Sheng Wang
2020-03-13 – 2021-09-13 · Chronic Hepatitis B
What this study did
NCT00931229 · National Health Research Institutes, Taiwan
2009-06 – 2017-12 · Non-Hodgkin's Lymphoma
What this study did
NCT03018821 · Xi'an Traditional Medicine Hospital
2017-01 – 2017-12 · Hepatitis B, Chronic
What this study did
NCT01918631 · Chinese University of Hong Kong
2013-08 – 2017-01-31 · Chronic Heptitis B
What this study did
NCT01243281 · Chulalongkorn University
2011-03 – 2013-12 · Chronic Hepatitis B
What this study did
NCT01813487 · Genexine, Inc.
2013-02 – 2013-07 · Chronic Hepatitis B
What this study did
NCT01139203 · Shanghai Jiao Tong University School of Medicine
2009-08 – 2012-12 · Liver Transplantation, Hepatitis B
What this study did
NCT00824707 · Eastern Hepatobiliary Surgery Hospital
2008-12 – 2010-12 · Primary Liver Cancer
What this study did
NCT01013272 · The University of Hong Kong
2007-06 – 2010-07 · Hepatitis B, Chronic
What this study did
NCT01018381 · The 108 Military Central Hospital
2006-06 – 2009-11 · Hepatocellular Carcinoma, Hepatitis B
What this study did
Other / comorbidity
NCT05453448 · Xiangya Hospital of Central South University
2022-05-01 – 2022-05-30 · Antiviral Drugs
What this study did
NCT04405011 · National Taiwan University Hospital
2018-08-01 – 2020-12-28 · HBV/HCV Co-infection
What this study did
NCT03509688 · The First Hospital of Jilin University
2014-11 – 2017-12 · Hepatitis
What this study did
Used as active comparator (34)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (7)
Chronic Hepatitis B
NCT04392700 · Sun Yat-sen University
2019-07-25 – 2024-07-25 · Hepatocellular Carcinoma Recurrent
What this study did
NCT03236610 · Uijeongbu St. Mary Hospital
2016-01-01 – 2019-06-30 · Proportion of Patients With a Sustained Virological Response (Serum HBV DNA <20 IU/mL) at Week 48
What this study did
NCT01595685 · Asan Medical Center
2012-05 – 2014-12 · Chronic Viral Hepatitis B Without Delta-agent
What this study did
NCT01480284 · GlaxoSmithKline
2011-11 – 2014-11 · Hepatitis B, Chronic
What this study did
NCT01892241 · Third Affiliated Hospital, Sun Yat-Sen University
2010-01 – 2013-02 · Antiviral Treatment of Chronic Hepatitis B
What this study did
NCT00412529 · Novartis Pharmaceuticals
2006-12 – 2008-02 · Hepatitis B, Chronic Hepatitis B
What this study did
Other / comorbidity
NCT07493109 · Ou Bai, MD/PHD
2026-05-30 – 2030-09-30 · Diffuse Large B-Cell Lymphoma (DLBCL)
What this study did
Phase 2 (3)
Chronic Hepatitis B
NCT01242787 · LG Life Sciences
2010-08 – 2012-09 · Chronic Hepatitis B
What this study did
NCT01026610 · LG Life Sciences
2009-08 – 2011-05 · Chronic Hepatitis B
What this study did
Phase 1/2 (3)
Chronic Hepatitis B
NCT04536532 · Sunshine Lake Pharma Co., Ltd.
2020-10-09 – 2023-03-12 · Hepatitis B, Chronic
What this study did
NCT02615639 · Third Affiliated Hospital, Sun Yat-Sen University
2015-11 – 2018-11 · Chronic Hepatitis B
What this study did
NCT02881008 · Hepatera Ltd.
2012-11-14 – 2014-10-04 · Chronic Hepatitis B
What this study did
Phase 1 (3)
Chronic Hepatitis B
NCT05391360 · Sunshine Lake Pharma Co., Ltd.
2021-10-11 – 2023-01-17 · Hepatitis B, Chronic
What this study did
NCT03272009 · Enyo Pharma
2017-09-21 – 2018-07-30 · Hepatitis B, Chronic
What this study did
Other / comorbidity
NCT02586363 · Seoul St. Mary's Hospital
2015-11 – 2016-03 · Healthy
What this study did
Phase 4 (10)
Chronic Hepatitis B
NCT06000657 · Daewoong Pharmaceutical Co. LTD.
2023-08-28 – 2025-02-03 · Hepatitis B, Chronic
What this study did
NCT03084250 · Shanghai Nanhui Nanhua Hospital
2017-03-10 – 2023-12-01 · Hepatitis B
What this study did
NCT02505009 · Chang Gung Memorial Hospital
2015-05-01 – 2018-12-21 · Chronic Hepatitis B
What this study did
NCT01639092 · Asan Medical Center
2012-09-28 – 2018-03-29 · Chronic Viral Hepatitis B Without Delta-agent
What this study did
NCT02588937 · Chong Kun Dang Pharmaceutical
2015-10 – 2017-06 · Hepatitis B, Chronic
What this study did
NCT02523547 · Hanmi Pharmaceutical Company Limited
2015-01 – 2017-02 · Chronic Hepatitis B
What this study did
NCT02850848 · Yung Shin Pharm. Ind. Co., Ltd.
2015-12 – 2016-02 · Hepatitis B
What this study did
NCT01588912 · Pusan National University Yangsan Hospital
2012-04 – 2014-12 · Chronic Hepatitis B
What this study did
NCT00986778 · Bristol-Myers Squibb
2009-12 – 2014-06 · Hepatitis B, Chronic
What this study did
NCT01266005 · Bukwang Pharmaceutical
2009-08 – 2014-01 · Chronic Hepatitis B
What this study did
Early phase / not applicable (8)
Chronic Hepatitis B
NCT05793268 · E-DA Hospital
2022-12-20 – 2026-12 · Chronic Hepatitis b
What this study did
NCT03920618 · Third Affiliated Hospital, Sun Yat-Sen University
2019-02-21 – 2024-12-31 · Hepatitis B, Acute-On-Chronic Liver Failure
What this study did
NCT05494528 · National Taiwan University Hospital
2021-05-04 – 2024-12-30 · Chronic Hepatitis B Virus Infection
What this study did
NCT04501224 · Third Affiliated Hospital, Sun Yat-Sen University
2020-08-03 – 2024-04-30 · Chronic Hepatitis b, Cirrhosis Due to Hepatitis B
What this study did
NCT04196998 · Third Affiliated Hospital, Sun Yat-Sen University
2019-01-01 – 2023-12 · Hepatitis B, Compensated Cirrhosis
What this study did
NCT03847246 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
2018-12-04 – 2018-12-28 · Chronic Hepatitis b
What this study did
NCT01599130 · Sun Yat-sen University
2012-07 – 2014-04 · Hepatitis B
What this study did
Appears in other studies (27)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (2)
Chronic Hepatitis B
NCT07095855 · Shanghai Zhimeng Biopharma, Inc.
2025-08 – 2030-01 · Chronic Hepatitis B
What this study did
Other / comorbidity
NCT04539119 · Ruijin Hospital
2020-07-03 – 2024-09-01 · B-cell Lymphoma, HBV
What this study did
Phase 2 (15)
Chronic Hepatitis B
NCT05484466 · Shanghai Zhimeng Biopharma, Inc.
2022-11-11 – 2024-12-30 · Hepatitis B, Chronic
What this study did
NCT05404919 · University of Pennsylvania
2022-09-06 – 2024-08-01 · Lung Transplant, Hepatitis B
What this study did
NCT04202653 · Tongji Hospital
2020-01-01 – 2023-12-31 · Chronic Hepatitis b
What this study did
NCT05107778 · Ascletis Pharmaceuticals Co., Ltd.
2022-01-10 – 2023-12-14 · Hepatitis B, Chronic
What this study did
NCT04147208 · Sunshine Lake Pharma Co., Ltd.
2019-02-28 – 2023-09-14 · Chronic HBV Infection
What this study did
NCT04180150 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
2019-11-18 – 2021-12-31 · Chronic Hepatitis B
What this study did
NCT04398134 · Assembly Biosciences
2020-08-28 – 2021-12-28 · Chronic Hepatitis B
What this study did
NCT04465916 · Enyo Pharma
2020-05-12 – 2021-11-25 · Hepatitis B, Chronic
What this study did
NCT03361956 · Janssen Sciences Ireland UC
2018-02-13 – 2020-08-13 · Hepatitis B
What this study did
NCT02391805 · Hoffmann-La Roche
2015-05-17 – 2017-10-16 · Hepatitis B, Chronic
What this study did
NCT02604199 · Arrowhead Pharmaceuticals
2015-09 – 2017-01 · Hepatitis B
What this study did
NCT02452528 · Arrowhead Pharmaceuticals
2015-08 – 2016-12 · Chronic Hepatitis B
What this study did
NCT02604212 · Arrowhead Pharmaceuticals
2015-11 – 2016-12 · Hepatitis B
What this study did
NCT01217632 · Kyntra Bio
2010-08 – 2015-06 · Liver Fibrosis Due to Chronic Hepatitis B Infection
What this study did
Phase 4 (9)
Chronic Hepatitis B
NCT03349008 · Cttq
2017-11-25 – 2020-05-31 · Chronic Hepatitis b, Liver Inflammation
What this study did
NCT03253250 · Huashan Hospital
2017-09-01 – 2019-12 · Chronic Hepatitis b, Hepatic Carcinoma
What this study did
NCT02532413 · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
2015-07 – 2017-08 · Chronic Hepatitis B
What this study did
NCT02360592 · Tongji Hospital
2013-06 – 2017-04 · Hepatitis B, Chronic
What this study did
Other / comorbidity
NCT05687409 · First Affiliated Hospital of Zhejiang University
2019-11-24 – 2022-10-24 · Cirrhosis, Liver, Metagonimiasis
What this study did
NCT02945982 · ShuGuang Hospital
2018-04-05 – 2021-06 · Portal Hypertension
What this study did
NCT01938781 · Beijing Friendship Hospital
2013-06 – 2016-12 · Liver Fibrosis
What this study did
NCT01938820 · Beijing Friendship Hospital
2013-06 – 2016-12 · Liver Cirrhosis
What this study did
NCT01943617 · Beijing Friendship Hospital
2013-06 – 2016-12 · Liver Cirrhosis
What this study did
Early phase / not applicable (1)
Chronic Hepatitis B
NCT03568578 · Peking University First Hospital
2018-01-28 – 2021-09-30 · Hepatitis B, Liver Fibrosis
What this study did

Competitive landscape

7 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Chronic Hepatitis B: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Entecavir (Baraclude): this drugApprovedSmall moleculeHBV polymerase (reverse transcriptase)not yet gradedNo reviewed efficacy summary in this indication
Hepatitis B Immune Globulin (HepaGam B)ApprovedProtein / enzyme therapeuticHBsAgnot yet gradedNo reviewed efficacy summary in this indication
Interferon Alfa-2b (Intron A)ApprovedBiologic (subtype unspecified)Type I interferon receptornot yet gradedNo reviewed efficacy summary in this indication
Lamivudine (Epivir-HBV)
ApprovedUS marketing discontinued
Small moleculeHBV polymerase (reverse transcriptase)not yet gradedNo reviewed efficacy summary in this indication
Peginterferon Alfa-2a (Pegasys)Approved—Type I interferon receptorPartial signalFeatured results are non-efficacy only in this race
Tenofovir Alafenamide (Vemlidy)ApprovedSmall moleculeHBV polymerase (reverse transcriptase)Reliable signalFeatured results are non-efficacy only in this race
Tenofovir Disoproxil Fumarate (Viread)ApprovedSmall moleculeHIV reverse transcriptase (RT)Reliable signal
NCT00116805: Percentage of Participants With HBV DNA < 400 Copies/mL and Histological Improvement (2-point Reduction in Knodell Necroinflammatory Score Without Worsening in Knodell Fibrosis Score) at Week 48 (Baseline; Week 48): TDF-TDF 66.5 percentage of participants | ADV 10 mg 12.2 percentage of participants
NCT00117676: Percentage of Participants With HBV DNA < 400 Copies/mL and Histological Improvement (2-point Reduction in Knodell Necroinflammatory Score Without Worsening in Knodell Fibrosis Score) at Week 48 (Baseline; Week 48): TDF-TDF — Yes: 70.8 percentage of participants; No: 29.2 percentage of participants | ADV-TDF — Yes: 48.8 percentage of participants; No: 51.2 percentage of participants
Besifovir Dipivoxil (Besivo)Phase 3Small moleculeHBV polymerase (reverse transcriptase)Partial signal
NCT01937806: Primary endpoint at week 48: 80.9% with besifovir vs 84.9% with tenofovir disoproxil fumarate met the virologic response endpoint, showing non-inferiority (Ahn et al., Clin Gastroenterol Hepatol 2019).
Hepatitis B Immune Globulin (I.V.-Hepabig)Phase 3Polyclonal Antibody (human Hepatitis B Immunoglobulin)HBsAgnot yet gradedNo reviewed efficacy summary in this indication
Tenofovir Amibufenamide (Hengmu)Phase 3Small moleculeHBV polymerase (reverse transcriptase)not yet gradedNo reviewed efficacy summary in this indication
TQA3605Phase 3—HBV core proteinnot yet gradedNo reviewed efficacy summary in this indication
TVAX-008Phase 3VaccineHepatitis B virus antigens (HBsAg + HBcAg)not yet gradedNo reviewed efficacy summary in this indication
AHB-171Phase 2RNA / oligonucleotideHBV RNAnot yet gradedNo reviewed efficacy summary in this indication
Daplusiran / TomligisiranPhase 2RNA / oligonucleotideHBV RNA (X and S transcripts)not yet gradedNo reviewed efficacy summary in this indication
EnvafolimabPhase 2Monoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
HepalatidePhase 2PeptideNTCPnot yet gradedNo reviewed efficacy summary in this indication
Libevitug (HH-003)Phase 2Monoclonal antibodyHBV/HDV large envelope protein (PreS1 domain)not yet gradedNo reviewed efficacy summary in this indication
MetacavirPhase 2Small moleculeHBV reverse transcriptase (nucleoside analog)not yet gradedNo reviewed efficacy summary in this indication
REP 2139-MgPhase 2—HBsAg release (nucleic acid polymer)not yet gradedNo reviewed efficacy summary in this indication
T101Phase 2Biologic (subtype unspecified)HBV core, polymerase and envelope antigensnot yet gradedNo reviewed efficacy summary in this indication
TQA3810Phase 2—TLR8not yet gradedNo reviewed efficacy summary in this indication
CRMA-1001Phase 1/2Gene therapy / editingHBV genome (cccDNA and integrated DNA)not yet gradedNo reviewed efficacy summary in this indication
HepadvaxPhase 1/2VaccineHBsAg (PreS) immunizationnot yet gradedNo reviewed efficacy summary in this indication
Human Serum Albumin / Interferon Alpha2b Fusion ProteinPhase 1/2Biologic (subtype unspecified)Type I interferon receptornot yet gradedNo reviewed efficacy summary in this indication
LW231Phase 1/2——not yet gradedNo reviewed efficacy summary in this indication
PA1010Phase 1/2——not yet gradedNo reviewed efficacy summary in this indication
TQA3038Phase 1/2——not yet gradedNo reviewed efficacy summary in this indication
ACT201Phase 1RNA / oligonucleotideHBsAgnot yet gradedNo reviewed efficacy summary in this indication
CB06-036Phase 1—TLR8not yet gradedNo reviewed efficacy summary in this indication
DA-2803Phase 1——not yet gradedNo reviewed efficacy summary in this indication
Entecavir (Cavir)
Phase 1(overall)
Small moleculeHBV polymerase (reverse transcriptase)not yet gradedNo reviewed efficacy summary in this indication
HECN30227Phase 1——not yet gradedNo reviewed efficacy summary in this indication
SA1211Phase 1RNA / oligonucleotideHepatitis B virus RNA (dual-target siRNA)not yet gradedNo reviewed efficacy summary in this indication
TVAX-028Phase 1——not yet gradedNo reviewed efficacy summary in this indication
Adefovir Dipivoxil (Hepsera)DiscontinuedSmall moleculeHBV polymerase (reverse transcriptase)not yet gradedNo reviewed efficacy summary in this indication
Obeticholic Acid (Ocaliva)Discontinued—FXRnot yet gradedNo reviewed efficacy summary in this indication
PamrevlumabDiscontinuedMonoclonal antibodyCTGFnot yet gradedNo reviewed efficacy summary in this indication
Telbivudine (Tyzeka)Discontinued—HBV polymerase (reverse transcriptase)Partial signal
NCT00076336: Protocol composite at week 52 (HBV DNA <10,000 copies/mL, normal ALT, Child-Turcotte-Pugh score improved or stable), telbivudine vs lamivudine, ITT missing=failure: 56.2% vs 54.0%, non-inferiority not achieved (Chan et al., Aliment Pharmacol Ther 2012). missed

Upcoming events

(11 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Entecavir (Baraclude) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 2Chronic Hepatitis BActive not recruiting
Est. primary completion 2026-12 · NCT05453435 · CT.gov ↗
What to watch
2027 (6)
January 2027 (1)
Phase 4Chronic Hepatitis BRecruiting
Est. primary completion 2027-01-19 · NCT07816094 · CT.gov ↗
What to watch
May 2027 (1)
Phase 3Chronic Hepatitis BRecruiting
Est. primary completion 2027-05-15 · NCT06966232 · CT.gov ↗
What to watch
August 2027 (1)
Phase 4Chronic Hepatitis BRecruiting
Est. primary completion 2027-08 · NCT07189377 · CT.gov ↗
What to watch
September 2027 (1)
Early phase / not applicableChronic Hepatitis BNot yet recruiting
Est. primary completion 2027-09-30 · NCT07253220 · CT.gov ↗
What to watch
December 2027 (2)
Phase 2Chronic Hepatitis BNot yet recruiting
Est. primary completion 2027-12-31 · NCT07267208 · CT.gov ↗
What to watch
Phase 4Chronic Hepatitis BRecruiting
Est. primary completion 2027-12-31 · NCT03933384 · CT.gov ↗
What to watch
2028 (2)
September 2028 (1)
Phase 3Chronic Hepatitis BNot yet recruiting
Est. primary completion 2028-09 · NCT07797231 · CT.gov ↗
What to watch
December 2028 (1)
Early phase / not applicableChronic Hepatitis BEnrolling by invitation
Est. primary completion 2028-12-31 · NCT04942886 · CT.gov ↗
What to watch
2030 (2)
December 2030 (2)
Phase 4Chronic Hepatitis BNot yet recruiting
Est. primary completion 2030-12-31 · NCT07345624 · CT.gov ↗
What to watch
Phase 4Chronic Hepatitis BNot yet recruiting
Est. primary completion 2030-12-31 · NCT07345611 · CT.gov ↗
What to watch

See the full readout calendar ↗